Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.78 |
| ▸ | PDE5A | O76074 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 4/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12431194 | 0.90 | HSP90AB1 (0.79) | HSP90AB1PDE5ASMN1; SMN2GHSRHPSE | |
| SCHEMBL13437206 | 0.89 | HSP90AB1 (0.78) | HSP90AB1PDE5ASMN1; SMN2HPSEMETAP2 | |
| SCHEMBL12430894 | 0.89 | HSP90AB1 (0.78) | HSP90AB1PDE5ASMN1; SMN2GHSRHPSE | |
| SCHEMBL13437212 | 0.89 | HSP90AB1 (0.78) | HSP90AB1PDE5ASMN1; SMN2GHSRHPSE | |
| SCHEMBL13437166 | 0.87 | HSP90AB1 (1.00) | HSP90AB1PDE5ASMN1; SMN2HPSEMETAP2 | |
| SCHEMBL13437213 | 0.86 | HSP90AB1 (0.81) | HSP90AB1PDE5AHPSEMETAP2METAP1 | |
| SCHEMBL12430606 | 0.86 | HSP90AB1 (0.80) | HSP90AB1PDE5ASMN1; SMN2HPSEMETAP2 | |
| SCHEMBL13437154 | 0.86 | HSP90AB1 (0.76) | HSP90AB1PDE5ASMN1; SMN2GHSRHPSE | |
| SCHEMBL13437167 | 0.86 | HSP90AB1 (0.85) | HSP90AB1PDE5ASMN1; SMN2HPSEMETAP2 | |
| SCHEMBL13437200 | 0.85 | HSP90AB1 (0.74) | HSP90AB1PDE5ASMN1; SMN2GHSRHPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888579-B1 | NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF | AVENTIS PHARMA SA (FR) | 2011-08-03 | — | — | EP | disclosed |
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885PDE5A 2779/4885SMN1; SMN2 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.